Roche's investigational medicine, fenebrutinib, has reportedly shown success in a phase iii trial for primary progressive multiple sclerosis, potentially reducing disability progression. The treatment, a BTK inhibitor, may be on track for approval. Details of the trial's outcome and the medicine's effects, including its impact on relapses, are emerging, with some reports suggesting a significant reduction in relapse frequency.